Two Sigma Advisers LP Purchases 282,100 Shares of Invivyd, Inc. (NASDAQ:IVVD)

Two Sigma Advisers LP increased its position in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 1,276.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 304,200 shares of the company's stock after buying an additional 282,100 shares during the period. Two Sigma Advisers LP owned 0.25% of Invivyd worth $135,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after acquiring an additional 9,207 shares during the period. Jane Street Group LLC lifted its position in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after purchasing an additional 87,358 shares during the period. Renaissance Technologies LLC bought a new stake in Invivyd during the fourth quarter worth about $74,000. JPMorgan Chase & Co. lifted its position in Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company's stock worth $114,000 after purchasing an additional 222,375 shares during the period. Finally, Deutsche Bank AG lifted its position in Invivyd by 35.2% during the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after purchasing an additional 227,463 shares during the period. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Stock Performance

Shares of Invivyd stock traded down $0.04 on Wednesday, hitting $0.87. The stock had a trading volume of 1,183,256 shares, compared to its average volume of 4,530,709. The firm has a market capitalization of $104.25 million, a P/E ratio of -0.44 and a beta of 0.63. The stock has a 50 day moving average of $0.70 and a 200 day moving average of $0.75. Invivyd, Inc. has a twelve month low of $0.35 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Equities analysts expect that Invivyd, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IVVD. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Invivyd in a research report on Friday, May 16th. HC Wainwright lowered their target price on Invivyd from $10.00 to $5.00 and set a "buy" rating for the company in a research note on Wednesday, May 28th.

Invivyd Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.